Alessio C.
- Country
- Italy
- Department
- UOC Oncologia Medica
Research Overview
- Phase 2 Open‑Label Multicohort Study of Rinatabart Sesutecan Monotherapy in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer
- Phase II Randomized, Double-Blind Study of BMS-986315 and Nivolumab with Chemotherapy in Stage IV or Recurrent Non-Small Cell Lung Cancer
- Randomized Phase 3 Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancer Post-PD-1/PD-L1 Inhibitor Progression
Data & Insights
Has run more than one trial at 174 of 383 partner sites.
Specializations
Advanced Lung Cancer Treatment
This investigator specializes in treating metastatic non-small cell lung cancer (NSCLC), with particular expertise in managing cases where conventional treatments have shown limited effectiveness.
- PD-L1 expression targeted therapies
- Advanced stage NSCLC management
- Metastatic disease treatment strategies
Their work encompasses various therapeutic approaches for treating locally-advanced and metastatic forms of NSCLC.
Immunotherapy Innovation
The investigator focuses on developing novel immunotherapy combinations for lung cancer treatment, including research into PD-1/PD-L1 inhibitors and innovative therapeutic agents.
- Combination immunotherapy approaches
- Treatment resistance mechanisms
- Immune checkpoint inhibition
Their research explores new pathways in immunotherapy effectiveness for lung cancer patients.
Therapeutic Development
The investigator specializes in evaluating emerging therapeutic combinations for lung cancer treatment, incorporating both established and investigational agents.
- Chemotherapy optimization
- Novel drug combinations
- Treatment sequencing strategies
Their expertise extends to developing treatment protocols for various stages of NSCLC.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.